Request Demo
Last update 09 May 2026
Anti CD22 CAR-T cell therapy (Hebei Senlang Biotechnology)
Last update 09 May 2026
Overview
Basic Info
Drug Type CAR-T |
Synonyms Anti CD22 CART cell Hebei Senlang Biotechnology, CD22 CART Hebei Senlang Biotechnology |
Target |
Action inhibitors |
Mechanism CD22 inhibitors(CD22 inhibitors), Gene transference(Gene transference), T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Sequence Code 71180linker
Sequence Code 133477linker
Sequence Code 524515404
Sequence Code 524515405
Sequence Code 524515406
Sequence Code 524515407ScFv
Related
5
Clinical Trials associated with Anti CD22 CAR-T cell therapy (Hebei Senlang Biotechnology)NCT05388695
To Observe the Long-term Efficacy and Safety of Dual-target Chimeric Antigen Receptor T Cells in the Treatment of Refractory Relapsed B Cell Hematologic Tumors
NCT04546906
Safety and Efficacy Study of CD22 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT04626739
An Open, Uncontrolled, Multicenter Clinical Trial to Explore the Safety, Efficacy, and Remission Phase of Chimeric Antigen Receptor T Cell (CAR-T) in the Treatment of Relapsed Refractory (R/R) Non-Hodgkin Lymphoma (NHL)
100 Clinical Results associated with Anti CD22 CAR-T cell therapy (Hebei Senlang Biotechnology)
Login to view more data
100 Translational Medicine associated with Anti CD22 CAR-T cell therapy (Hebei Senlang Biotechnology)
Login to view more data
100 Patents (Medical) associated with Anti CD22 CAR-T cell therapy (Hebei Senlang Biotechnology)
Login to view more data
100 Deals associated with Anti CD22 CAR-T cell therapy (Hebei Senlang Biotechnology)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Acute Lymphoblastic Leukemia | Phase 2 | China | 26 Mar 2020 | |
| B-Cell Malignant Neoplasm | Phase 1 | China | 08 Apr 2022 | |
| Non-Hodgkin's lymphoma refractory | Phase 1 | China | 01 Apr 2020 | |
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | Phase 1 | China | 01 Apr 2020 | |
| Recurrent Adult Acute Lymphoblastic Leukemia | Phase 1 | China | 01 Apr 2020 | |
| Recurrent Childhood Acute Lymphoblastic Leukemia | Phase 1 | China | 01 Apr 2020 | |
| refractory acute lymphoid leukemia in relapse | Phase 1 | China | 01 Apr 2020 | |
| Refractory Indolent Adult Non-Hodgkin Lymphoma | Phase 1 | China | 01 Apr 2020 | |
| Non-Hodgkin Lymphoma | Phase 1 | China | 11 Mar 2020 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free